Patent: 9,644,008
✉ Email this page to a colleague
Summary for Patent: 9,644,008
Title: | Deglycosylated hemagglutinin and manufacture thereof |
Abstract: | The invention provides a deglycosylated hemagglutinin, wherein the glycosylation site(s) on the stem region is removed. The deglycosylated hemagglutinin may induce neutralizing antibody against influenza virus, and cross-reactive protection against different virus. The invention also provides a method for manufacturing deglycosylated hemagglutinin, comprising aligning two or more hemagglutinin stem sequences of influenza virus, identifying the high conserved N-glycosylation site, and removing the high conserved N-glycosylation site. Thus, the N-glycosylation site cannot be glycosylated. |
Inventor(s): | Wu; Suh-Chin (Hsinchu, TW), Liu; Wen-Chun (Hsinchu, TW), Huang; Yun-Ju (Hsinchu, TW) |
Assignee: | National Tsing Hua University (Hsinchu, TW) |
Application Number: | 14/201,276 |
Patent Claims: | see list of patent claims |
Details for Patent 9,644,008
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Seqirus Vaccines Limited | FLUVIRIN | influenza virus vaccine | Injection | 103837 | 11/03/1998 | ⤷ Try a Trial | 2033-12-27 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/09/1999 | ⤷ Try a Trial | 2033-12-27 |
Sanofi Pasteur Inc. | FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT | influenza virus vaccine | Injection | 103914 | 12/23/1909 | ⤷ Try a Trial | 2033-12-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |